Skip to main content
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. — Investor Relations & Filings

Ticker · BCAX ISIN · US0554771032 US Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2024-07-22 Regulatory Filings
Country US United States of America
Listing US BCAX

About Bicara Therapeutics Inc.

https://www.bicara.com/

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class, dual-action biologics for cancer treatment. The company engineers bifunctional therapies that combine the precision of targeted treatments with the activation of a potent and durable anti-tumor immune response. This approach is designed to deliver therapeutic impact directly within the tumor microenvironment, with a primary focus on developing treatments for patients with solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from Bicara Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) staff comments regarding their Draft Registration Statement on Form S-1. The letter addresses specific SEC comments on disclosures, clinical trial data, risk factors, financial condition, and other regulatory compliance matters related to the company's planned initial public offering (IPO). The presence of references to Form S-1, IPO, clinical trial disclosures, and detailed responses to SEC comments clearly identifies this document as a comment letter and amendment submission related to a registration statement, not a financial report or earnings release. This type of document is regulatory correspondence related to the registration process for securities offerings and does not fit into categories like Annual Report, Earnings Release, or Management Discussion and Analysis. It is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2024-07-22 English
Regulatory Filings 2024
Regulatory Filings
2024-07-09 English
Regulatory Filings 2024
Regulatory Filings
2024-07-05 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement on Form S-1 submitted to the SEC by Bicara Therapeutics Inc. The Form S-1 is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. The text includes detailed prospectus information, risk factors, management discussion, financial data, and underwriting details typical of an IPO registration statement. It is not an annual report, earnings release, or any other type of financial report but a registration statement for capital raising. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2024-06-10 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.